Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 699

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Metformin: update on mechanisms of action and repurposing potential

Open access
Foretz, Marc, Guigas, Bruno, Viollet, Benoit·2023·Nature Reviews Endocrinology

Abstract

The liver and gut are the main target organs for metformin. Mitochondria and lysosomes are the organelle targets in the glucose-lowering effect of metformin. Host–gut microbiota interactions contribute to metformin’s therapeutic effects. Metformin has anti-inflammatory and immunomodulatory properties in various immune-related diseases through AMPK-dependent and AMPK-independent mechanisms involving both the innate and adaptive immune systems. Metformin therapy in patients with type 2 diabetes mellitus enhances the release of GDF15, which might facilitate weight loss but is not required for the effect in reducing blood levels of glucose. This Review highlights the latest advances in our understanding of the mechanisms of action of metformin. Potential repurposing of metformin for other indications is also discussed. Currently, metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) in most guidelines and is used daily by >200 million patients. Surprisingly, the mechanisms underlying its therapeutic action are complex and are still not fully understood. Early evidence highlighted the liver as the major organ involved in the effect of metformin on reducing blood levels of glucose. However, increasing evidence points towards other sites of action that might also have an important role, including the gastrointestinal tract, the gut microbial communities and the tissue-resident immune cells. At the molecular level, it seems that the mechanisms of action vary depending on the dose of metformin used and duration of treatment. Initial studies have shown that metformin targets hepatic mitochondria; however, the identification of a novel target at low concentrations of metformin at the lysosome surface might reveal a new mechanism of action. Based on the efficacy and safety records in T2DM, attention has been given to the repurposing of metformin as part of adjunct therapy for the treatment of cancer, age-related diseases, inflammatory diseases and COVID-19. In this Review, we highlight the latest advances in our understanding of the mechanisms of action of metformin and discuss potential emerging novel therapeutic uses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-023-00833-4

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 699

Metadata

Authors
Foretz, M., Guigas, B., & Viollet, B.
Venue
Nature Reviews Endocrinology
Published
2023-05-02
Volume
19
Issue
8
Pages
460-476
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W4367676125
Cited by
699
References
52
FWCI
17.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.